
Two young Harvard professors are coming for the supplements industry. Dr. Jonathan Gootenberg and Dr. Omar Abudayyeh run a joint lab at Harvard Medical School, have co-founded 4 biotechs, and raised over $300M to develop genetic medicines and diagnostics. But what surprised me most: they think like consumer tech founders, not academics. They start with what people actually want and work backwards from there. And best of all? They’re totally longevity-pilled. In this week’s episode of the Free Radicals podcast, we discuss the biology of aging, the future of longevity therapeutics, and how Harvard can bring legitimacy to the supplements industry.As PhD students at Harvard in Feng Zhang and Aviv Regev’s labs, Jonathan and Omar pioneered research on programmable targeted genetic engineering with CRISPR. Now Jonathan and Omar lead a joint lab at Harvard, where they develop molecular and artificial intelligence based approaches to program biology, unravel cellular aging, rejuvenate hair, develop next-gen therapeutics, and decode biological complexity with virtual cells.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

How GLP-1s are paving the way for the new era of biotech - Elliot Hershberg, Investor & Blogger

There are no longevity drugs today, but there will be soon - Dr. James Peyer, Cambrian Founder

Aging kills EVERYONE, but only because we're not trying hard enough - Longevity Activist Nathan Cheng

The one-man biotech is only 10 years away - a16z-backed founder Kexin Huang
Free AI-powered recaps of Free Radicals and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.